Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875866 | 0.86 | ALDH1A1 (0.60) | NOS1MAPTADRB3GABRA5GABRB2 | |
| SCHEMBL11914560 | 0.83 | ADRB3 (0.78) | NOS1ADRB3GABRA5GABRB2HSD17B10 | |
| SCHEMBL8148068 | 0.83 | LTA4H (0.58) | MAPTTP53KDM4ECA1CA2 | |
| Hydrochloric Acid SCHEMBL28729981 | 0.82 | ADRB3 (0.76) | NOS1ADRB3GABRA5GABRB2HSD17B10 | |
| SCHEMBL16609245 | 0.79 | ADRB3 (0.73) | ADRB3ADRB2ADRB1SMN1; SMN2 | |
| SCHEMBL4871513 | 0.78 | NOS1 (0.61) | NOS1MAPTADRB3GABRA5GABRB2 | |
| SCHEMBL28193160 | 0.78 | ADRB3 (0.48) | NOS1MAPTADRB3GABRA5GABRB2 | |
| SCHEMBL4456667 | 0.77 | ADRB3 (0.69) | NOS1MAPTADRB3ADRB2ADRB1 | |
| SCHEMBL1769583 | 0.76 | GABRA5 (0.54) | MAPTADRB3GABRA5GABRB2HSD17B10 | |
| SCHEMBL1769580 | 0.76 | GABRA5 (0.54) | MAPTADRB3GABRA5GABRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | SCHMITZ FRANZ ULRICH | 2010-01-07 | — | — | US | disclosed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1971597-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, HAVCR2 | NOS1 1922/4885MAPT 1615/4885ADRB3 3310/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | NOS1 1922/4885MAPT 1615/4885ADRB3 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.